PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$38.00 USD
+0.09 (0.24%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $38.05 +0.05 (0.13%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
PTC Therapeutics, Inc. [PTCT]
Reports for Purchase
Showing records 141 - 147 ( 147 total )
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Q2:13 Update - Ataluren Potentially The First DMD Drug to Launch
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Aug. 12
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
SMA Collaboration $10M Milestone Achieved - PTCT Remains Undervalued and Misunderstood - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Initiating Coverage with OUTPERFORM Rating, $55 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C